Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
Funding Amount
Not stated
Deadline
February 17, 2028
501 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Nonprofits (501(c)(3))
- City & township governments
- Small businesses
- Public & Indian housing authorities
- Public colleges & universities
- For-profit businesses
- Special district governments
- School districts
Geography
- Non-domestic (non-U.S.) components of U.S.
Not eligible / not funded
- Not eligible: Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
- Not eligible: Organizations are not eligible to apply.
- Not eligible: Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Overview
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease. Applicants will identify a human disease relevant undruggable target class and develop a method or agent that is selective for one or more targets within that target class. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: PAR-25-442
- Instrument: grant
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Focus Areas & Funding Uses
Fields of Work
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
National Institutes of Health
Amount
Varies
Deadline
October 6, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed). Now let's win it.